EndoPore Platform

About Vitarka Therapeutics

Vitarka Therapeutics is an early-stage biotech tackling one of drug development's fundamental hurdles: efficient intracellular delivery. Its core platform, EndoPore, utilizes engineered pore-forming proteins to actively transport therapeutic payloads from the endosome into the cytosol, aiming for enhanced potency and tumor selectivity. Led by a seasoned team with deep drug development and venture creation experience, the company is in the pre-clinical fundraising stage, advancing its platform for oncology applications with potential expansion into other disease areas. Vitarka's value proposition centers on a delivery mechanism that could improve upon the limitations of current technologies like antibody-drug conjugates (ADCs) and lipid nanoparticles (LNPs).

Therapeutic Areas